ストックスクリーナーアプリを入手
780.28
0.67%
-5.23
アフターアワーズ：
780.30
0.02
+0.00%
前日終値:
$785.51
開ける：
$783.17
24時間の取引高:
586.74K
Relative Volume:
0.62
時価総額：
$82.49B
収益：
$14.34B
当期純損益:
$4.50B
株価収益率:
18.77
EPS:
41.5626
ネットキャッシュフロー:
$3.77B
1週間 パフォーマンス:
+3.35%
1か月 パフォーマンス:
-2.04%
6か月 パフォーマンス:
+38.59%
1年 パフォーマンス:
+9.90%
1日の値動き範囲:
$775.50
$790.00
1週間の範囲:
$742.74
$790.00
52週間の値動き範囲:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | アップグレード | BofA Securities | Underperform → Buy |
| 2025-12-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 開始されました | HSBC Securities | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $975.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Regeneron stock price target to $975 on Dupixent growth - Investing.com
Candriam S.C.A. Has $95.30 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bessemer Group Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Savant Capital LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Thrivent Financial for Lutherans Sells 1,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Murphy Pohlad Asset Management LLC - MarketBeat
Prime Capital Investment Advisors LLC Buys 11,835 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Data On EYLEA HD Dosing Shapes Retinal Disease Outlook - simplywall.st
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback - Yahoo Finance
Regeneron (REGN) Q2 2025 Earnings Call Transcript - AOL.com
Regeneron holiday party tops Albany Capital Center revenue list - The Business Journals
Bronte Capital Management Pty Ltd. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks - TipRanks
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - Finviz
REGENERON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
CytomX Therapeutics to Present at Upcoming February Conferences - GlobeNewswire Inc.
Mediolanum International Funds Ltd Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Q4 2025 Beat And New EYLEA HD Data - simplywall.st
The Truth About Regeneron Pharmaceuticals Inc: Why Wall Street Will Not Shut Up About REGN - AD HOC NEWS
Disabled electrician sues Regeneron and contractor - Westfair Communications
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $742 to $950 - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Feb 02, 2026 BMO Maintains Outperform on REGN (Regeneron Pharmaceuticals, Inc.) - Meyka
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating - MSN
Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron (REGN)? - simplywall.st
Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target - TipRanks
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Promising 15% Upside as Analysts Rally Behind Biotech Giant - DirectorsTalk Interviews
Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? - Stocktwits
Where Regeneron Pharmaceuticals Stands With Analysts - Benzinga
JP Morgan Raises Price Target for REGN to $950 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $950.00 at JPMorgan Chase & Co. - MarketBeat
Regeneron Pharmaceuticals (REGN) Gets Analyst Boost with Revised Price Target | REGN Stock News - GuruFocus
Oppenheimer Reaffirms Outperform Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $769.00 at Morgan Stanley - MarketBeat
Analyst Matthew Harrison Maintains Equal-Weight Rating for REGN | REGN Stock News - GuruFocus
Wells Fargo Raises Price Target for Regeneron Pharmaceuticals (R - GuruFocus
REGN: Cantor Fitzgerald Raises Price Target to $800, Maintains O - GuruFocus
Cantor Fitzgerald Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $800.00 - MarketBeat
Truist Financial Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Truist Securities Maintains Buy Rating on REGN, Lowers Price Target | REGN Stock News - GuruFocus
Regeneron (REGN) Boosts Dividend by 6.8%, Expects Strong Growth - GuruFocus
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $850, Maintains Overweight Rating - marketscreener.com
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $916, Maintains Outperform Rating - marketscreener.com
Oppenheimer Raises Price Target on Regeneron Pharmaceuticals to $865 From $750, Keeps Outperform Rating - marketscreener.com
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
2.07%
1.48%
大文字化:
|
ボリューム (24 時間):